Adma Biologics reported $45.33M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Adma Biologics USD 45.33M 4.05M Mar/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Novavax USD 17.53M 219.91M Dec/2025
Omeros USD -32.23M 23.81M Sep/2024
Takeda JPY 113.2B 137.52B Jun/2026